YM-348 je lek sa indazolnim osnovom koji deluje kao potentan i selektivan agonist5-HT2Creceptor, sa EC50 vrednošću od 1 nM i 15x selektivnošću u odnosu na 5-HT2A. On je umereno selektivan 3x u odnosu na blisko srodni 5-HT2B receptor.[1][2] On ispoljava termogeno i anoreksično dejsto u životinjskim studijama, što ga čini potencijalno korisnim u lečenju gojaznosti.[3][4][5][6]
^Kimura, Y; Hatanaka, K; Naitou, Y; Maeno, K; Shimada, I; Koakutsu, A; Wanibuchi, F; Yamaguchi, T (2004). „Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist”. European journal of pharmacology. 483 (1): 37—43. PMID14709324.
^Shimada, I; Maeno, K; Kazuta, K; Kubota, H; Kimizuka, T; Kimura, Y; Hatanaka, K; Naitou, Y; Wanibuchi, F (2008). „Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo2,3-gindazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists”. Bioorganic & medicinal chemistry. 16 (4): 1966—82. PMID18035544. doi:10.1016/j.bmc.2007.10.100.
^Hayashi A, Sonoda R, Kimura Y, Takasu T, Suzuki M, Sasamata M, Miyata K (2004). „Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats”. Brain research. 1011 (2): 221—7. PMID15157808. doi:10.1016/j.brainres.2004.03.032.
^Smith, BM; Thomsen, WJ; Grottick, AJ (2006). „The potential use of selective 5-HT2C agonists in treating obesity”. Expert opinion on investigational drugs. 15 (3): 257—66. PMID16503763. doi:10.1517/13543784.15.3.257.
^Wacker, DA; Miller, KJ (2008). „Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases”. Current opinion in drug discovery & development. 11 (4): 438—45. PMID18600561.
